Helen Heslop, MD

Adjunct Professor of Medicine, Academic Institute
Full Affiliate Member, Research Institute
Houston Methodist


Dr. Heslop's initial faculty appointment was as Assistant Member of the Division of Bone Marrow Transplantation in the Department of Hematology-Oncology at the St. Jude Children's Research Hospital, in Memphis in 1991. She was promoted to Associate Member in 1994. She also held an appointment as Associate Professor in the Department of Pediatrics at the University of Tennessee in Memphis. Dr. Heslop received her current appointments at the Baylor College of Medicine in Houston, Texas in 1997. She was named as the first Dan L. Duncan Chair for Baylor College of Medicine in 2006.

Description of Research

Dr. Heslop's research centers on adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy. She currently directs a Lymphoma SPORE program and a program project grant from the NCI, as well as a Specialized Center of Research from the Leukemia and Lymphoma Society. Her research focus is to develop safe and effective T-cell immunotherapies for lymphoma and other Epstein-Barr virus-associated malignancies, including Hodgkin's Disease and nasopharyngeal cancer. Dr. Heslop also runs studies using third party CTLs to treat viral infections after transplant.

Areas Of Expertise

Cancer Adoptive immunotherapy Effector cells Hemopoietic stem cell transplantation

Data mining for second malignancies after CAR-T
Heslop, HE 2024, , Blood, vol. 143, no. 20, pp. 2023-2024. https://doi.org/10.1182/blood.2024024446

Long-Term Follow-Up for Recipients of Genetically Modified Cells: A Team Effort
Heslop, HE 2024, , Transplantation and Cellular Therapy, vol. 30, no. 3, pp. 247-249. https://doi.org/10.1016/j.jtct.2024.02.006

A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help
Curran, KJ, Nikiforow, S, Bachier, C, Hsu, YM, Maloney, D, Maus, MV, McCarthy, P, Porter, D, Shi, P, Shpall, EJ, William, B, Wacker, K, Warkentin, P & Heslop, HE 2024, , Blood Advances, vol. 8, no. 4, pp. 1053-1061. https://doi.org/10.1182/bloodadvances.2023010401

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
Levine, BL, Pasquini, MC, Connolly, JE, Porter, DL, Gustafson, MP, Boelens, JJ, Horwitz, EM, Grupp, SA, Maus, MV, Locke, FL, Ciceri, F, Ruggeri, A, Snowden, J, Heslop, HE, Mackall, CL, June, CH, Sureda, AM & Perales, MA 2024, , Nature Medicine, vol. 30, no. 2, pp. 338-341. https://doi.org/10.1038/s41591-023-02767-w

Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy
Kapadia, CD, Rosas, G, Thakkar, SG, Wu, M, Torrano, V, Wang, T, Grilley, BJ, Heslop, HE, Ramos, CA, Goodell, MA & Lulla, PD 2024, , Cytotherapy, vol. 26, no. 3, pp. 261-265. https://doi.org/10.1016/j.jcyt.2023.11.013

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
Hill, LQC, Rouce, RH, Wu, MJ, Wang, T, Ma, R, Zhang, H, Mehta, B, Lapteva, N, Mei, Z, Smith, TS, Yang, L, Srinivasan, M, Burkhardt, PM, Ramos, CA, Lulla, P, Arredondo, M, Grilley, B, Heslop, HE, Brenner, MK & Mamonkin, M 2024, , Blood, vol. 143, no. 13, pp. 1231-1241. https://doi.org/10.1182/blood.2023022204

Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis
Mo, F, Tsai, CT, Zheng, R, Cheng, C, Heslop, HE, Brenner, MK, Mamonkin, M & Watanabe, N 2024, , Cytotherapy. https://doi.org/10.1016/j.jcyt.2024.03.006

Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
Hegde, M, Navai, S, DeRenzo, C, Joseph, SK, Sanber, K, Wu, M, Gad, AZ, Janeway, KA, Campbell, M, Mullikin, D, Nawas, Z, Robertson, C, Mathew, PR, Zhang, H, Mehta, B, Bhat, RR, Major, A, Shree, A, Gerken, C, Kalra, M, Chakraborty, R, Thakkar, SG, Dakhova, O, Salsman, VS, Grilley, B, Lapteva, N, Gee, A, Dotti, G, Bao, R, Salem, AH, Wang, T, Brenner, MK, Heslop, HE, Wels, WS, Hicks, MJ, Gottschalk, S & Ahmed, N 2024, , Nature Cancer. https://doi.org/10.1038/s43018-024-00749-6

Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors
Miller, A, Daum, R, Wang, T, Wu, M, Tat, C, Pfeiffer, T, Navai, S, Heczey, A, Hegde, M, Ahmed, N, Whittle, SB, Hill, LQ, Martinez, C, Krance, R, Ramos, CA, Rouce, RH, Lulla, P, Heslop, HE, Omer, B & Shekar, M 2024, , Cytotherapy. https://doi.org/10.1016/j.jcyt.2024.04.075

Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients
Vasileiou, S, Hill, LQ, Kuvalekar, M, Workineh, AG, Watanabe, A, Velazquez, Y, Lulla, S, Mooney, K, Lapteva, N, Grilley, BJ, Heslop, HE, Rooney, CM, Brenner, MK, Eagar, TN, Carrum, G, Grimes, KA, Leen, AM & Lulla, P 2023, , Haematologica, vol. 108, no. 7, pp. 1840-1850. https://doi.org/10.3324/haematol.2022.281946

Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival
Martinez, C, Aguayo-Hiraldo, P, Chaimowitz, N, Forbes, L, Rider, N, Nicholas, S, Seeborg, F, Chinen, J, Chinn, I, Davis, C, Roseblatt, H, Noroski, L, Omer, B, John, T, Yassine, K, Naik, S, Craddock, J, Bhar, S, Allen, C, Ahmed, N, Sasa, G, Steffin, D, Doherty, E, George, A, Salem, B, Friend, B, Hegde, M, Brenner, MK, Heslop, HE, Leen, A, Peña, A, Wu, M, Hanson, IC & Krance, RA 2023, , Blood Advances, vol. 7, no. 9, pp. 1823-1830. https://doi.org/10.1182/BLOODADVANCES.2022009038

Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: Implications for T-cell immunotherapy
Sharma, S, Woods, M, Mehta, NU, Sauer, T, Parikh, KS, Schmuck-Henneresse, M, Zhang, H, Mehta, B, Brenner, MK, Heslop, HE & Rooney, CM 2023, , Journal for immunotherapy of cancer, vol. 11, no. 4, jitc-2022-006267. https://doi.org/10.1136/jitc-2022-006267

Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies
Nikiforow, S, Frigault, MJ, Frey, NV, Gardner, RA, Komanduri, KV, Perales, MA, Kebriaei, P, Warkentin, PI, Pasquini, M, Aho, JL, Levine, BL, Heslop, HE, Hlucky, TL, Habucky, K, Gharibo, M, Jagasia, M & Locke, FL 2023, , Transplantation and Cellular Therapy, vol. 29, no. 4, pp. 228-239. https://doi.org/10.1016/j.jtct.2023.01.021

Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies
Wang, D, Porter, CE, Lim, B, Shaw, AR, Robertson, CS, Woods, ML, Xu, Y, Biegert, GGW, Morita, D, Wang, T, Grilley, BJ, Heslop, H, Brenner, MK & Suzuki, M 2023, , Science advances, vol. 9, no. 13, eade6790, pp. eade6790. https://doi.org/10.1126/sciadv.ade6790

Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials
Cornetta, K, Yao, J, House, K, Duffy, L, Adusumilli, PS, Beyer, R, Booth, C, Brenner, M, Curran, K, Grilley, B, Heslop, H, Hinrichs, CS, Kaplan, RN, Kiem, HP, Kochenderfer, JN, Kohn, DB, Mailankody, S, Norberg, SM, OCearbhaill, RE, Pappas, J, Park, J, Ramos, C, Ribas, A, Rivière, I, Rosenberg, SA, Sauter, C, Shah, NN, Slovin, SF, Thrasher, A, Williams, DA & Lin, TY 2023, , Molecular Therapy, vol. 31, no. 3, pp. 801-809. https://doi.org/10.1016/j.ymthe.2022.12.006

Introduction to a review series on banked allogeneic immune effector cells
Heslop, HE 2023, , Blood, vol. 141, no. 8, pp. 811-812. https://doi.org/10.1182/blood.2023019604

Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting
Pfeiffer, T, Tzannou, I, Wu, M, Ramos, C, Sasa, G, Martinez, C, Lulla, P, Krance, RA, Scherer, L, Ruderfer, D, Naik, S, Bocchini, C, Fraser, IP, Patel, B, Ward, D, Wang, T, Heslop, HE, Leen, AM & Omer, B 2023, , Clinical Cancer Research, vol. 29, no. 2, pp. 3240330. https://doi.org/10.1158/1078-0432.CCR-22-2415

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation
Mo, F, Watanabe, N, Omdahl, KI, Burkhardt, PM, Ding, X, Hayase, E, Panoskaltsis-Mortari, A, Jenq, RR, Heslop, HE, Kean, LS, Brenner, M, Tkachev, V & Mamonkin, M 2023, , Blood, vol. 141, no. 10, pp. 1194-1208. https://doi.org/10.1182/blood.2022016052

Introduction to a How I Treat series on emergent CAR T-cell toxicities
Heslop, HE 2023, , Blood, vol. 141, no. 20, pp. 2405-2407. https://doi.org/10.1182/blood.2023020228

Moving CAR-Ts to the outpatient clinic
Llaurador, GA, Heslop, HE & Steffin, DH 2023, , British Journal of Haematology, vol. 203, no. 4, pp. 507-508. https://doi.org/10.1111/bjh.19129